Wed, Oct 22, 2014, 12:57 AM EDT - U.S. Markets open in 8 hrs 33 mins

Recent

% | $
Quotes you view appear here for quick access.

Sarepta Therapeutics, Inc. Message Board

  • vskomarovsky vskomarovsky Jun 24, 2013 6:26 PM Flag

    The Week's Biotech Winner and Loser - from MF

    Winner: Sarepta

    Sarepta shares have soared over 800% in the past year thanks solely to the Duchenne muscular dystrophy drug eteplirsen. DMD is a degenerative X-linked muscle disease that usually leaves the young male patients wheelchair-bound. The life expectancy is under 30.

    Eteplirsen’s new data comes from a phase 2b extension study that was testing the drug against placebo using the six-minute walk, an important DMD metric. Trial patients would walk for six minutes and have the distance measured over the course of 84 weeks. Boys taking eteplirsen showed an improvement of 46.4 meters over the placebo arm. The boys also showed a relatively stable overall decline in walking distance.

    Sarepta is overly dependent on eteplirsen’s success. But the efficacy data continues to impress and the safety profile hasn’t thrown up any warning signs. An FDA approval would serve a disease that currently has no real treatment options, and cement Sarepta’s developer reputation at the same time.

    Sentiment: Strong Buy

 
SRPT
22.49-0.34(-1.49%)Oct 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.